Healthcare reform, unveiled, finally

Article

Four months after House Speaker Nancy Pelosi declared “We have to pass the bill so you can find out what’s in it,” a congressional panel has released the first chart illustrating the 2,801 page health care law President Obama signed into law in March. Check out the video…

Four months after House Speaker Nancy Pelosi declared “We have to pass the bill so you can find out what’s in it,” a congressional panel has released the first chart illustrating the 2,801 page health care law President Obama signed into law in March. Check out the video…

In this video, House Representative Kevin Brady discusses complexity of Obama-care...

One of the most pressing and heretofore unanswered questions is how the proposed $500 billion cuts will to Medicare affect cancer patients, the majority of whom are beneficiaries of the program. Then there is the nagging and maddening issue of getting fair compensation for the intricate services performed in the oncology clinic…

Look here for ASCO coverage on CMS cuts...

On July 1, the Centers for Medicare and Medicaid Services (CMS) released its proposed physician fee schedule for 2010, which includes a 6% cut in Medicare payments for medical oncology services. This cut is on top of a scheduled 21% reduction to the Medicare conversion factor due to the flawed sustainable growth rate (SGR) formula.

While Congress has indicated a willingness to provide a fix to the SGR to avert the 21% reduction, it is unclear how or when this would happen. Even taken alone, the 6 percent cut in overall payment, if implemented, would severely hamper the ability of oncologists to continue providing care to people with cancer.

The editors of Practice & Policy welcome comments from our viewership. Please forward any comment or editorial you wished published to Ronald.piana@ubm.com


 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content